Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Global University Venturing

Design Therapeutics drafts IPO filing

UW Madison’s small-molecule therapy spinout has raised $170m in venture funding since emerging from stealth less than a year ago.


Mar 10, 2021

OSU orchestrates 13 spinouts

Ohio State University spun out a total of 13 companies in the last fiscal year and now has a portfolio with a record 98 active businesses.

Mar 10, 2021

Innosphere inks Oklahoma State deal

Oklahoma State University has struck a partnership with Innosphere Ventures to support the commercialisation of its research.

Mar 10, 2021

Neophore negotiates $21m series B

The immuno-oncology company, based on University of Turin research, has completed a $21m series B round led by Claris Ventures.

Mar 10, 2021

Quench Bio dismantles business

Max Planck spinout Quench Bio will wind down after its target proved undruggable and will return capital to investors, which include AbbVie Ventures.

Mar 10, 2021

IonQ signs up to $2bn reverse merger

Hyundai, Kia and GV are contributing to a $350 PIPE in support of a reverse merger that will value the Maryland and Duke-linked company at $2bn.

Mar 9, 2021

Planted harvests $18.3m series A

Vorwerk Ventures and Blue Horizon Ventures have co-led a series A round for the ETH Zurich spinout selling plant-based meat products.

Mar 9, 2021

Coursera to class as public company

University of Pennyslvania and Caltech are in line for exits when Stanford’s online education spinout lists on the New York Stock Exchange.

Mar 8, 2021

SEE Fund receives Tsinghua's backing

Tsinghua Holdings has helped the venture fund, managed by DeePhi founder Yao Song, reach a $30.9m close.

Mar 8, 2021

Lava Therapeutics flows toward public markets

Immuno-oncology therapy developer Lava Therapeutics has filed for a $100m IPO, having been set up in 2016 to exploit Amsterdam University Medical Centers research.

Mar 5, 2021

Century Therapeutics sells Bayer on $160m round

Versant Ventures, which incubated the cell-based immunotherapy developer based on Harvard and Stanford research, has backed a $160m round.

Mar 5, 2021
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here